This is in contrast to BRAF V600E mutation [19–21] or TERT promoter mutations [12, 13, 22, 23], which are associated with aggressiveness and poor clinical outcomes of thyroid cancer. This evidence concerns the gene BRAF and thyroid gland carcinoma.